Not FDA-approved
Hormones & metabolism
Ipamorelin
Evidence
Early trials only
Class
Growth hormone secretagogue
KEY TAKEAWAY
Ipamorelin is a selective growth hormone secretagogue. It raises growth hormone in healthy volunteers but has no approved use, and a phase 2 trial for post-surgery recovery did not lead to approval.
Written by the Veylo editorial team · Updated
November 2026
What it is
A synthetic ghrelin receptor agonist
Studied for
Growth hormone stimulation and post-surgery bowel recovery
Key fact
Raises growth hormone levels; clinical benefit not established
Route
Injection (research use)
Evidence strength
Early trials only
Ipamorelin is a five-amino-acid peptide that mimics ghrelin at the growth hormone secretagogue receptor.
It prompts the pituitary to release growth hormone in pulses without strongly raising cortisol or prolactin in early studies.
Ipamorelin is not approved by the FDA and is not an approved treatment for any condition.
Studied for growth hormone deficiency and post-operative ileus. It has no approved medical use.
Headache, flushing and dizziness have been reported. Long-term effects of raising growth hormone are not well studied.
Primary literature for this entry is being compiled.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.